Epstein-Barr virus latent membrane protein 1 (LMP1) activates NF-kB signaling pathways through two C-terminal regions, CTAR1 and CTAR2. Previous studies have demonstrated that BS69, a multidomain cellular protein, regulates LMP1/CTAR2mediated NF-kB activation by interfering with the complex formation between TRADD and LMP1/CTAR2. Here, we found that BS69 directly interacted with the LMP1/CTAR1 domain and regulated LMP1/CTAR1-mediated NF-kB activation and subsequent IL-6 production. Regarding the mechanisms involved, we found that BS69 directly interacted with TRAF3, a negative regulator of NF-kB activation. Furthermore, small-interfering RNA-mediated knockdown experiments revealed that TRAF3 was involved in the BS69-mediated suppression of LMP1/CTAR1-induced NF-kB activation.
Introduction
Epstein-Barr virus (EBV) is strongly linked to the development of multiple malignancies, including post-transplant lymphoma, Hodgkin disease and nasopharyngeal carcinoma. EBV-encoded latent membrane protein 1 (LMP1) is expressed in many EBV-associated tumor cells and is responsible for the majority of their altered cellular growth properties. Structurally, LMP1 is an integral membrane protein of 386 amino acids (aa) that consists of a short cytoplasmic N-terminal domain (aa 1-24), six transmembrane domains (aa 25-186) and a long cytoplasmic C-terminal tail (aa 187-386) [1] [2] [3] . The cytoplasmic C-terminal tail contains two C-terminal activation regions (CTARs), CTAR1 and CTAR2 [1, 4] . Signals through these two CTAR domains have been reported to induce p100 and p105 NF-kB precursors and generate p52 and p50 subunits, respectively [5, 6] , indicating that LMP1 is involved in both canonical and non-canonical activation of NF-kB pathways. CTAR1 contains a tumor necrosis factor receptor (TNFR)-associated factor (TRAF)-binding motif, and can bind to TRAF1, TRAF2, TRAF3 and TRAF5 [1, [7] [8] [9] [10] . CTAR2 interacts with TNFRassociated death domain protein (TRADD), receptor-interacting protein (RIP) [11, 12] and BS69 [13] . These CTAR1-and CTAR2-associated molecules have the ability to induce or suppress LMP1-mediated NF-kB activation. Recently, we identified STAP-2, an adaptor protein, as a new binding partner of both CTAR1 and CTAR2, and demonstrated that STAP-2 negatively regulates LMP1-mediated NF-kB activation [14] .
BS69, a multidomain cellular protein containing PHD, Bromo, PWWP and MYND domains, was originally identified as an adenovirus E1A-binding protein that inhibits the transactivation function of E1A [15] . Furthermore, the C-terminal MYND domain of BS69 was shown to bind to the PXLXP motif existing in E1A, the EBV-encoded EBNA2 and the Myc-related cellular protein MGA [16] . Importantly, BS69 interacts with EBV-encoded LMP1 through its MYND domain and acts as a scaffold protein in the LMP1-mediated JNK pathway [13] by interacting with TRAF6. In addition, we previously reported that BS69 is able to negatively regulate LMP1-mediated NF-kB activation by displacing TRADD from the CTAR2 domain of LMP1 [17] .
In the present study, we newly found that BS69 directly interacts with the LMP1/CTAR1 domain and downregulates LMP1/CTAR1-mediated NF-kB activation.
We further found that TRAF3 directly interacts with BS69 and is involved in the BS69mediated suppression of LMP1/CTAR1-induced NF-kB activation. Taken together, BS69 is likely to act as an endogenous negative regulator of both canonical and noncanonical NF-kB activation mediated by LMP1.
Materials and methods

2.1.Reagents and antibodies
Expression vectors for BS69 and NF-kB-LUC were kindly provided by H. Shibuya (Tokyo Medical and Dental University, Tokyo, Japan) and T. Fujita (Kyoto University, Kyoto, Japan) [17, 18, 19] . Epitope-tagged LMP1 and a series of TRAF constructs were described previously [14] . The following primary antibodies were obtained commercially: anti-p52, anti-Bcl-2, anti-nucleoporin, anti-TRAF3 and anti-Myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA); anti-FLAG mAb (M2) and anti-HA antibody (Sigma-Aldrich, St. Louis, MO); and anti-actin mAb (Chemicon International, Temecula, CA).
Cell culture and transfection
A human cervix carcinoma cell line (HeLa), human embryonic kidney carcinoma cell line (293T) were maintained in DMEM containing 10% FCS. HeLa cells were transfected using jetPEI (PolyPlus-transfection, Strasbourg, France) according to the manufacturer's instructions. 293T cells were transfected using a standard calcium precipitation protocol [19] . A human B-lymphoblastoid EBV-transformed cell line (SKW6-CL4) was maintained in RPMI1640 containing 10% FCS.
Transfection of small-interfering RNAs (siRNAs) and luciferase assays
The siRNAs targeting human BS69 (#1 and #2) used in this study were as follows: BS69#1, 5'-GGAUGAAGUCGGACCACAATT-3'; BS69#2, 5'-GAAGUUAUGAAGAGUUCAATT-3'; TRAF3, 5'-GGAAGAUUCGCGACUACAATT-3'. HeLa cells were plated on 24-well plates at 2x10 4 cells/well and incubated with an siRNA (15 pM) -Lipofectamine 2000 (Invitrogen, Carlsbad, CA) mixture at 37°C for 4 h, followed by the addition of fresh medium containing 10% FCS. HeLa cells were further transfected with or without NF-kB-LUC with or without LMP1 using jetPEI as described in the section above. At 24 h after transfection, the cells were harvested and assayed for their luciferase activities using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer's instructions. 293T cells were transfected as described in the section above. The cells were harvested at 36 h after transfection, lysed in 50 ml of Reporter Lysis Buffer (Promega) and assayed for their luciferase and b-galactosidase activities according to the manufacturer's instructions. Three or more independent experiments were carried out for each assay. Human SKW6-CL4 B cells were transfected with a control siRNA or BS69 siRNA#2 (100 pM) using a MicroPorator according to the manufacturer's instructions.
Immunoprecipitation and immunoblotting
Immunoprecipitation and western blotting assays were performed as described previously [20] . The immunoprecipitates from cell lysates were resolved by SDS-PAGE and transferred to PVDF membranes (PerkinElmer, Boston, MA). The membranes were then immunoblotted with the different primary antibodies. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Millipore, Bedford, MA).
RNA isolation, RT-PCR and quantitative real-time PCR
After cell harvesting, total RNA samples were extracted using Iso-Gen (Nippon Gene, Tokyo, Japan) and subjected to RT-PCR using an RT-PCR High -Plus-Kit (TOYOBO, Tokyo, Japan) [14] . Primers used for RT-PCR were: BS69: 
Results and discussion
3.1. BS69 interacts with the LMP1/CTAR1 domain and negatively regulates LMP1/CTAR1-induced NF-kB activation
We previously showed that BS69 suppresses LMP1-induced canonical NF-kB activation, which is mediated through the cytoplasmic C-terminal CTAR2 domain of LMP1 [17] . Although BS69 has been believed to bind to the CTAR2 domain, the yeast two-hybrid assays employed the cytoplasmic carboxyl tail of LMP1 (aa 187-386), containing both CTAR1 and CTAR2, as bait [13] . These facts led us to investigate whether BS69 physically and functionally interacts with the LMP1/CTAR1 domain, another functional domain for NF-kB activation. First, we examined whether BS69 binds to a truncated LMP1 (aa 1-231) lacking the CTAR2 domain. Coimmunoprecipitation experiments were performed using 293T cells transfected with expression vectors for HA-tagged BS69 together with FLAG-tagged LMP1 wild-type (WT), LMP1 (aa 1-231) or empty vector. The immunoprecipitates for LMP1 WT contained BS69 protein ( Fig. 1A and B ), as expected from previous data [13, 17] .
Similarly, the immunoprecipitates for LMP1 (aa 1-231) contained BS69 protein, indicating that BS69 was still able to associate with LMP1 in the absence of the CTAR2 domain in 293T cells.
Next, we investigated the effects of BS69 on LMP1/CTAR1-induced NF-kB activation using transient reporter assays with NF-kB-LUC. The NF-kB-LUC activities were induced by the expression of LMP1 (aa 1-231) in 293T and HeLa cells (Fig. 1C ), although NF-kB activation induced by LMP1 (aa 1-231) was lower than LMP1 WT.
Indeed, LMP1 WT showed approximately 2-3-fold higher activation than LMP1 (aa 1-231), when cells were transfected with the same amount of plasmids (data not shown).
Importantly, these LMP1/CTAR1-induced NF-kB-LUC activities were significantly reduced by co-expression of BS69 in a dose-dependent manner, suggesting that BS69 Therefore, we tested the possible associations of BS69 with a series of TRAFs. 293T cells were transfected with FLAG-tagged TRAF1, TRAF2, TRAF3, TRAF5 or TRAF6 together with HA-tagged BS69. Western blot analyses with an anti-HA antibody revealed that BS69 physically interacted with all the TRAFs examined (Fig. 3A) .
We also examined the effects of TRAFs on LMP1WT-and LMP1/CTAR1-induced NF-kB activation in HeLa cells. As shown in Fig. 3B However, no synergistic effect was observed by combined silencing of BS69 and TRAF3.
We further investigated which domains of TRAF3 mediated the interactions with BS69. HA-tagged BS69 and the respective FLAG-tagged TRAF3 mutants were transiently expressed in 293T cells. Immunoprecipitation with an anti-HA antibody followed by western blot analyses with an anti-FLAG antibody revealed that TRAF3 (D2-92), TRAF3 (D2-190), TRAF3 (D2-367) and TRAF3 (D422-568) as well as TRAF3
WT were able to bind to BS69. However, TRAF3 (D317-568) lost the ability to bind to BS69. These findings suggested that the binding site for BS69 on TRAF3 was mapped to a region (aa 368-421) in the N-terminal of the TRAF-binding domain (Fig. 4B ).
With regard to domains of TRAF3 mediated the interactions with LMP1/CTAR1, the Cterminal TRAF-binding domain of TRAF3 was clearly essential although the results for the N-terminal RING domain were complicated (data not shown). Therefore, these data demonstrate that TRAF3 directly interacts with the LMP1/CTAR1 and BS69.
Unlike many other TRAF family proteins that enhance NF-kB activation, TRAF3 has been reported to suppress TNFR family-induced NF-kB activation and was identified as a negative regulator of NF-kB by promoting its degradation [24] . Moreover, recent studies have indicated that the B cells in TRAF3 knockout mice develop splenomegaly and lymphadenopathy, in association with hyperglobulinemia and autoimmunity, suggesting a role for TRAF3 in B-cell homeostasis [25, 26] . With regard to LMP1 signaling, experiments involving TRAF3 overexpression have indicated that TRAF3 inhibits the NF-kB activation induced by LMP1. Furthermore, TRAF3 has been shown to negatively regulate LMP1 signaling by displacing TRAF1 and TRAF2 from CTAR1 [8] . In addition, TRAF3 is known to regulate LMP1 signaling through direct interactions with CTAR1 and indirect interactions with CTAR2 [25] . Based on the above information, we examined the effects of combined knockdown of BS69 and TRAF3 on the LMP1/CTAR1-induced NF-kB activation in HeLa cells. Interestingly, the reduction of endogenous TRAF3 caused a significant increase in LMP1 (aa 1-231)induced NF-kB activation but no significant effect of BS69 siRNA-mediated enhancement of LMP1 (aa 1-231)-induced NF-kB activation (Fig. 3D) , indicating that BS69 fails to suppress LMP1/CTAR1-induced NF-kB activation in the absence of TRAF3. Therefore, a BS69-TRAF3 complex may interact with LMP1/CTAR1 and be responsible for the regulation of LMP1/CTAR1-induced NF-kB activation. Taken together, these findings indicate that BS69 cooperates with TRAF3 in the regulation of LMP1/CTAR1-induced NF-kB activation.
Concluding remarks
In our previous study, we showed that BS69 suppresses LMP1-induced NF-kB activation by competing with the complex formation between TRADD and LMP1/CTAR2 [17] . Here, we have demonstrated novel functions of BS69, namely that it interacts with LMP1/CTAR1 and negatively regulates LMP1/CTAR1-mediated NF-kB activation. Regarding the inhibitory mechanisms, we found cooperative effects between BS69 and TRAF3. Therefore, BS69 can inhibit LMP1-induced NF-kB activation mediated through both the CTAR1 and CTAR2 domains. These suppressive effects of BS69 may be similar to the case for STAP-2, which we previously reported as a negative regulator of LMP1/CTAR1-and LMP1/CTAR2-induced NF-kB activation.
However, the molecular mechanisms underlying these effects are a little different. BS69 equally bound to all TRAF family proteins examined (TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6), while STAP-2 strongly interacted with TRAF1 and TRAF3 [14] .
The binding site for STAP-2 on TRAF3 was mapped to a narrow region (aa 317-367) between a leucine-zipper domain and a TRAF-binding domain [14] , while the binding site for BS69 was mapped to a region (aa 368-421) in the N-terminal portion of the TRAF-binding domain. Moreover, LMP1 expression upregulated STAP-2 expression, suggesting that STAP-2 plays a role in the defense of host cells against EBV after infection. In contrast, BS69 is constitutively expressed and may function in the defense of host cells against EBV under steady-state conditions. Our proposed mechanisms for the actions of BS69 on LMP1 signaling are illustrated in Fig. 4C . Our data suggest that BS69 may be a novel candidate for antiviral therapies aimed at regulating the EBV LMP1-induced NF-kB and JNK pathways. 
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